Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.74 AUD 8.82% Market Closed
Market Cap: 255.2m AUD
Have any thoughts about
Aroa Biosurgery Ltd?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Aroa Biosurgery Ltd

Revenue
76.4m NZD
Cost of Revenue
-10.2m NZD
Gross Profit
66.1m NZD
Operating Expenses
-76m NZD
Operating Income
-9.9m NZD
Other Expenses
2.3m NZD
Net Income
-7.6m NZD

Margins Comparison
Aroa Biosurgery Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
NZ
Aroa Biosurgery Ltd
ASX:ARX
255.2m AUD
87%
-13%
-10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
67%
28%
9%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
60%
19%
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
38%
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
-22%
-14%
Country NZ
Market Cap 255.2m AUD
Gross Margin
87%
Operating Margin
-13%
Net Margin
-10%
Country FR
Market Cap 6T USD
Gross Margin
0%
Operating Margin
-17 527%
Net Margin
-21 040%
Country US
Market Cap 318.1B USD
Gross Margin
67%
Operating Margin
28%
Net Margin
9%
Country US
Market Cap 142.2B USD
Gross Margin
60%
Operating Margin
19%
Net Margin
13%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Operating Margin
38%
Net Margin
0%
Country US
Market Cap 105.2B USD
Gross Margin
86%
Operating Margin
40%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Operating Margin
30%
Net Margin
34%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
Operating Margin
-22%
Net Margin
-14%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Aroa Biosurgery Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
NZ
Aroa Biosurgery Ltd
ASX:ARX
255.2m AUD
-8%
-7%
-10%
-14%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
56%
4%
15%
11%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
56%
5%
9%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
1%
0%
23%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
-3%
-2%
24%
-80%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
135.7B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-8%
-7%
-12%
-31%
Country NZ
Market Cap 255.2m AUD
ROE
-8%
ROA
-7%
ROCE
-10%
ROIC
-14%
Country FR
Market Cap 6T USD
ROE
115%
ROA
-391%
ROCE
275%
ROIC
3 093%
Country US
Market Cap 318.1B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
11%
Country US
Market Cap 142.2B USD
ROE
56%
ROA
5%
ROCE
9%
ROIC
10%
Country US
Market Cap 117.1B USD
ROE
1%
ROA
0%
ROCE
23%
ROIC
13%
Country US
Market Cap 105.2B USD
ROE
-3%
ROA
-2%
ROCE
24%
ROIC
-80%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 135.7B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 78.7B USD
ROE
17%
ROA
13%
ROCE
13%
ROIC
16%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 36.2B EUR
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top